Alterations in unbound free fatty acid profiles in CVD
Ended Project Grant Awarded Last action
- Award ID
- R43HL170882
- Recipient
-
Membrane Sciences, LLC UEI SCKQPDV2GGC8
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $585,984
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Patients with stable cardiovascular disease (CVD) have an elevated risk of a second event. The easiest method for screening risk in stable CVD patients would use biomarkers. However, no single marker has sufficient prognostic power. In this project we will determine whether profiles of unbound free fatty acids (ffau) can help predict the risk of adverse outcomes in patients with stable cardiovascular disease (CVD). Plasma free fatty acids (FFA) which are mostly bound to albumin have long been associated with cardiac ischemia. Although present at only NM concentrations, the ffau are the physiologically relevant fraction because the unbound and not the bound are transported into cells. We developed fluorescent probes (adifab) to measure ffau and found that ffau levels were associated with cardiovascular ischemia during ptca and in patients with stemi in timi II. Human plasma is composed of about 30 unique FFA. Because they have distinct biological effects, we have developed a method to determine the different ffau (profiles). The nhlbi provided US with plasma from 1200 patients (w/ clinical data) from the peace trial which sought to determine whether ACE inhibitors would improve outcomes in patients who had a cardiovascular event. We used our ffau profiling method to profile 200 of the peace patients. For most of the ffau there were no significant case (event) VS. Control (no event) differences. However, for unbound alpha linolenate (alnau) the average case mole fractions were more than twice controls (p
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $292,992 | |
| Original award | $292,992 |
Quick answers
Who received award R43HL170882?
R43HL170882 was awarded to Membrane Sciences, LLC by National Heart Lung and Blood Institute (National Institutes of Health) on August 1, 2023.
How much is award R43HL170882 worth?
$585,984 has been obligated on R43HL170882.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award